Conditions: Kidney Failure, Chronic Renal Insufficiency, Chronic
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 47
Healthy volunteers: yes

Brief summary:
The purpose of this study was to measure how much of the study drug, LY2409021, gets into the blood stream and how long it takes the body to get rid of it when given to participants with different levels of kidney function. There were five study groups. Each participant only enrolled in one group. Participants in groups 1 through 4 were healthy or have mild, moderate, or severe kidney disease. They completed one study period lasting about 29 days. Study group 5 enrolled participants with kidney disease who were on dialysis. They have completed two study periods which together last about 59 days. Screening was required within 21 days prior to the start of the study for all participants.

Detailed description:

Arms:
arm 1: Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study. arm 2: Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study. arm 3: Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study. arm 4: Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study. arm 5: Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.

Interventions: intervention 1: LY2409021
Intervention descriptions: intervention 1: Administered orally

Protocol document: